Zacks Investment Research. Image Source: Zacks Investment Research. Financial Considerations for AZN’s Acquisition of EsoBiotec. AstraZeneca will acquire EsoBiotec for up to $1 billion on a cash ...

EsoBiotec investors include Thuja Capital, UCB Ventures, Invivo Partners, Wallonie Entreprendre (WE), SambrInvest and Investsud. EsoBiotec’s proprietary ENaBL platform redefines adoptive cell ...

British drug major AstraZeneca said on Monday it has entered into a definitive agreement to acquire EsoBiotec, a Belgian biotech company, for up to $1 billion on a cash and debt-free basis. The ...

AstraZeneca PLC (LSE/STO/Nasdaq:LON: AZN), the global biopharmaceutical company, has announced the completion of its acquisition of EsoBiotec, a biotech company specializing in cell therapies, for a ...

EsoBiotec's pipeline features two first-in-class, combination candidates-ESO-TX101 and ESO-TX102-designed to build on the simultaneous engineering of T cells and monocytes to remodel the tumor ...

Poster talk will present safety and efficacy data for ENaBL-T, a lentiviral vector for in vivo engineering of BCMA CAR T cells, which supported the first in vivo BCMA CAR-T cell therapy clinical ...

EsoBiotec’s proprietary ENaBL platform redefines adoptive cell therapy, enabling single IV, off-the-shelf treatments that reduce costs, improve patient experience, ...

ESO-T01 is the first in vivo BCMA CAR-T candidate to reach the clinical stage. Early clinical data are expected in second half of 2025. MONT-SAINT-GUIBERT, Belgium, Dec. 11, 2024 (GLOBE NEWSWIRE) -- ...

EsoBiotec. Acquisition includes EsoBiotec’s world-leading in vivo delivery platform with potential to transform cell therapy. MONT-SAINT-GUIBERT, Belgium, March 17, 2025 (GLOBE NEWSWIRE) -- EsoBiotec ...

EsoBiotec's proprietary ENaBL platform redefines adoptive cell therapy, enabling single IV, off-the-shelf treatments that reduce costs, improve patient experience, ...